Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb 3;139(5):639-640.
doi: 10.1182/blood.2021014903.

Boosting BNT162b2 vaccine efficacy in CLL

Seema A Bhat  1 , Jennifer A Woyach  1
Affiliations
Editorial

Boosting BNT162b2 vaccine efficacy in CLL

Seema A Bhat et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.A.B. consulted for Pharmacyclics, Janssen, Beigene, and AstraZeneca, received honorarium for OncLive, and a travel grant from Arqule. J.A.W. receives research funding from Pharmacyclics, Janssen, Karyopharm, Morphosys, and Schrodinger and consults for Janssen, Pharmacyclics, Abbvie, AstraZeneca, Arqule, Beigene, Loxo, and Newave.

Figures

None
Potential strategies to improve vaccination efficacy in CLL. Even following 3 doses of mRNA vaccine, up to 37% of patients remain seronegative. Current areas of research include adding additional “booster” doses of vaccine and “mix and match” of different vaccine types. As well, long-acting monoclonal antibodies are a potential strategy for those who are unable to mount a vaccine response.
See this image and copyright information in PMC

Comment on

References

    1. Herishanu Y, Rahav G, Levi S, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022; 139(5):678-685. - PMC - PubMed
    1. Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia [published correction appears in Expert Rev Hematol. 2018;11(1):ix]. Expert Rev Hematol. 2018; 11(1):57-70. - PubMed
    1. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-1143. - PMC - PubMed
    1. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-3173. - PMC - PubMed
    1. Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35(3):737-746. - PubMed